ClinicalTrials.gg
RecruitingNCT06551285Updated Mar 17, 2026

Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome.

An interventional study of Ovapro (Lifepro) in Polycystic Ovary Syndrome and Metabolic Syndrome, sponsored by Celia Bañuls. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Celia Bañuls · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2024, registered Jul 2024).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Polycystic Ovary Syndrome with a site in Spain — 3 open to participants now, 3 under way, none of them phase 3. Polycystic Ovary Syndrome · Spain.

Planned enrollment
3rd of 10
120 · median 50
Started
2024
the only one that year
No phase
5 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Celia Bañuls

Among the 14 studies in Polycystic Ovary Syndrome with a site in Spain, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 5 with no phase, and was the 13th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

3 of the 14 studies in Polycystic Ovary Syndrome with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Polycystic Ovary Syndrome with a site in Spain, or all of them as a file.
02

Study summary

Polycystic Ovary Syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by elevated androgen levels due to ovarian overproduction. Although the pathophysiology of PCOS is not fully understood, it is estimated that insulin resistance (IR) occurs in 70-80% of PCOS cases, which may contribute to hyperandrogenism in affected women.

Women with PCOS and IR are more likely to develop metabolic syndrome, increasing the risk of diabetes, cardiovascular diseases, lipid profile deterioration, elevated inflammation levels, and greater oxidative stress.

The symptoms of PCOS are varied and differ among patients. Common symptoms include androgenic alopecia, hirsutism, acne, abdominal fat accumulation, and fertility issues. These physical manifestations and related problems have been associated with reduced quality of life and self-esteem in these women. The symptoms of PCOS can be improved through lifestyle changes aimed at enhancing insulin sensitivity, such as proper nutrition and regular physical exercise.

Some supplements, such as a combination of Myo-inositol and D-chiro-inositol in a 40:1 ratio, are being used to support the management of PCOS because they appear to improve insulin sensitivity, as well as reduce underlying inflammation and oxidative stress.

To determine whether nutritional intervention combined with inositol supplementation improves PCOS symptoms, various variables will be analyzed to assess improvements in oxidative stress markers, inflammation, lipid profile, hormonal profile, and microbiota. Additionally, if the metabolic profile improves, it is hypothesized that this could also enhance quality of life and self-esteem.

Read the detailed description

Polycystic Ovary Syndrome (PCOS) is an endocrine-metabolic disorder that affects many women of reproductive age. PCOS is not just a reproductive disorder but a systemic condition, as cases of PCOS have been described even in menopause, although its prevalence in post-reproductive stages is not high. The diagnosis of PCOS is made using the Rotterdam criteria, agreed upon in 2003 by ESHRE and ASRM (European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine). According to these criteria, a patient must meet two of the following three criteria to be diagnosed with PCOS: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian appearance.

The Rotterdam criteria are widely used but can sometimes lead to an erroneous diagnosis of PCOS. Therefore, in 2006, the AES (Androgen Excess Society) decided that, in addition to the 2003 Rotterdam criteria, hyperandrogenism-either physical or biochemical-was necessary for a PCOS diagnosis. Depending on the criteria used and the diversity of the population studied, epidemiological results can vary. Despite this variability, it is estimated that PCOS affects 6-12% of women of reproductive age.

The most common manifestations of PCOS include androgenic alopecia, hirsutism, acne, irregular cycles, or periods of amenorrhea. An ultrasound image showing polycystic ovarian morphology alone is insufficient for diagnosing PCOS. In polycystic ovaries, more than 12 follicles of 2-9 mm in size and increased ovarian volume (>10 ml) should be visualized using transvaginal ultrasound. Despite the complex and not fully understood pathophysiology of PCOS, two main types of alterations are identified.** On one hand, there is an accelerated release of gonadotropin-releasing hormone (GnRH), which leads to an increased release of luteinizing hormone (LH), resulting in greater androgen production, altered folliculogenesis, and long menstrual cycles or amenorrhea. On the other hand, there is an alteration in ovarian steroidogenesis and folliculogenesis due to increased activity of cytochrome P450c17, an enzyme involved in the synthesis of ovarian and adrenal androgens, leading to elevated androgen levels.

In 70-80% of PCOS cases, women present insulin resistance (IR), with 30-50% of these also exhibiting obesity. High body fat percentage and hyperinsulinemia play significant roles in the development and progression of PCOS. Chronically elevated insulin levels can be associated with elevated androgen levels in a bidirectional manner. Elevated insulin levels may stimulate LH production and increase the activity of the P450c17 enzyme in the ovaries and adrenal glands, resulting in reduced hepatic production of sex hormone-binding globulin (SHBG), which increases the amount of free androgens. Conversely, elevated androgens are associated with increased insulin resistance in the muscles, leading to poorer glucose uptake.

Obesity is considered an amplifying factor in the pathophysiology of PCOS. Adipose tissue is an endocrine organ, and a high amount of adipose tissue increases the production of inflammatory cytokines, which can worsen IR by interfering with glucose uptake. While 70-80% of women with PCOS have IR, there is a 20-30% subgroup without metabolic involvement. Women with PCOS who have a healthy body fat percentage also present with insulin resistance, suggesting that obesity is not the cause of PCOS.

PCOS is a syndrome with a significant genetic basis, complex, and multifactorial pathophysiology. Lifestyle benefits in improving symptoms and the syndrome's progression are an important therapeutic tool. PCOS directly affects the quality of life of patients due to the long-term symptoms and comorbidities associated with this condition, such as obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome (MS), and psychological and emotional issues. Consequently, women with PCOS generally have poorer health compared to those without the condition. Furthermore, comorbidities directly impact quality of life and individual perception of it.

To improve symptoms and prevent the comorbidities, the first line of treatment for patients with PCOS and IR should involve lifestyle modifications. Nutritional intervention and physical exercise are fundamental in maintaining a proper body composition, which can prevent the worsening of PCOS symptoms. The quality and composition of the diet are crucial, beyond the implications of body weight. A hypocaloric diet including low glycemic load foods has been shown to improve the homeostatic model assessment of insulin resistance (HOMA-IR), low-density lipoprotein (LDL) levels, triglycerides (TGC), cholesterol, and free androgen index (FAI). Improving lifestyle will directly impact body fat percentage, which, in turn, will improve hyperandrogenism and ovarian function.

Mental health disorders are highly prevalent among women with PCOS, particularly anxiety, depression, and sleep disorders. Sleep disturbances impact the onset and progression of anxiety and depression in PCOS patients; thus, treating sleep-related issues should be part of the overall treatment. Sleep deprivation is associated with an increased risk of IR, obesity, and type 2 diabetes (T2D). It has been observed that patients with PCOS have decreased melatonin levels in follicular fluid. Melatonin is a potent antioxidant that protects ovarian follicles during maturation. Therefore, sleep disorders can worsen insulin resistance and consequently exacerbate PCOS with metabolic involvement.

Additionally, the microbiota, through the production of various metabolites, impacts complex mechanisms such as hunger and satiety regulation, carbohydrate and lipid metabolism, which can directly affect body composition and PCOS symptoms. The gut microbiota can regulate up to 10% of the transcriptome and host genes involved in metabolism, proliferation, and immune response. Moreover, diet can modulate the gut microbiota composition in patients with PCOS and IR, as an increase in bifidobacteria correlates with improved insulin sensitivity and reduced inflammation. Short-chain fatty acids (SCFAs) such as acetate and butyrate, produced by beneficial gut microbiota, influence glycemia. Given the role of these metabolites in carbohydrate and lipid metabolism, achieving a healthy microbiota state could be a therapeutic goal to reduce systemic inflammation and improve IR.

The two specific inositol stereoisomers, Myo-inositol (MI) and D-chiro-inositol (DCI), act as second messengers of insulin. MI transforms into an insulin second messenger, Myo-inositol phosphoglycan (MI-IPG), which is involved in cellular glucose uptake, while DCI converts into another insulin second messenger, DCI-IPG, which is involved in glycogen synthesis. In patients with PCOS, there appears to be an increased epimerization of Myo-inositol (MI) to D-chiro-inositol (DCI) at the ovarian level due to insulin's effect. Consequently, there is an excess of DCI and a deficiency of MI, which can affect follicle-stimulating hormone (FSH) signaling and deteriorate oocyte quality. Therefore, inositol supplementation is considered an effective and safe method for improving PCOS symptoms by enhancing insulin sensitivity, follicular development, and oocyte maturation. This insulin-sensitizing effect of inositol can help normalize blood androgen levels and improve glycemia. Metformin is a common treatment for women with PCOS and IR. Recent results show that Myo-inositol can be as effective as metformin without its side effects. Both inositol and metformin can improve the metabolic and clinical profile of PCOS patients, as well as metabolic disorders related to diabetes.

Additionally, adequate vitamin D levels should also be considered in patients with PCOS, as vitamin D is involved in increasing the synthesis and release of insulin, enhances insulin receptor presence, and improves insulin response in glucose transport. Vitamin D indirectly affects carbohydrate metabolism by normalizing extracellular calcium levels and parathyroid hormone concentration. It also impacts systemic inflammation by inhibiting the production of pro-inflammatory cytokines, which could contribute to the development of IR. Patients with PCOS who took 20,000 IU of cholecalciferol (Vitamin D) weekly benefited from improved carbohydrate metabolism and better menstrual frequency. Combined supplementation of magnesium, zinc, calcium, and vitamin D in another study led to a significant reduction in total testosterone compared to placebo, although it did not affect sex hormone-binding globulin (SHBG) levels or the free androgen index (FAI). However, the combination of vitamin D and fish oil reduced inflammation markers in the body, such as serum C-reactive protein (CRP), downregulated interleukin 1 (IL-1), and total testosterone levels. A beneficial effect on mental health parameters was also observed, assessed through the Beck Depression Inventory. Available literature shows that zinc supplementation may be indicated in patients with PCOS, as zinc plays an important role in glucose and lipid metabolism. Zinc deficiency may play a significant role in PCOS pathophysiology and also serve as a prognostic marker for the syndrome. It appears that zinc levels in PCOS patients are significantly lower compared to healthy controls. Low zinc intake in individuals with high body fat percentage is associated with hyperinsulinemia, low-grade inflammation, and deterioration of the lipid profile. Zinc ions can act as insulin mimetics in adipocytes, stimulating lipogenesis and glucose transport through the translocation of glucose transporter 4 (GLUT4) to the plasma membrane.

In PCOS patients, there is known to be higher oxidative stress, which could worsen the symptoms of PCOS. Curcumin, extracted from turmeric (Curcuma longa), is a biologically active phytochemical with antioxidant properties. Studies with curcumin in animals have shown promising results, but in PCOS patients, the literature is inconclusive, and it is limited to suggesting that curcumin may have beneficial effects in the clinical management of PCOS symptoms.

03

Conditions studied

  • Polycystic Ovary Syndrome
  • Metabolic Syndrome

Keywords

  • Insulin resistance
  • Inflammation
  • Oxidative Stress
  • Intestinal microbiota
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 45 years.
  • Patients diagnosed with PCOS using the AE-PCOS diagnostic criteria (2009).
  • Patients who agree to participate in the study and sign the form after reading it.

Exclusion criteria

Exclusion Criteria:

  • Having been treated with medication or supplementation aimed at improving PCOS prior to the study (e.g., metformin, hormonal therapy, inositol, etc.).
  • Suffering from an infectious, hematological, inflammatory, or disease.
  • Having a severe organic disease.
  • Suffering from cardiovascular disease (heart attack, ischemia, thromboembolism).
  • Diabetes Mellitus.
  • Severe arterial hypertension.
  • Alcoholism.
  • Active smoking.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Dietary supplement in PCOS

    Subjects will recieve nutritional intervention by a registered dietitian and a supplement containing inositol, vitamin D, zinc, and curcumin for 3 months. The dietary intervention consists of healthy dietary recommendations and hipocaloric diet if needed (overweight, obesity).

    Dietary Supplement: Ovapro (Lifepro)

  • Placebo comparator
    Placebo in PCOS

    Subjects will recieve nutritional intervention by a registered dietitian and a supplement containing yellow colorant for 3 months. The dietary intervention consists of healthy dietary recommendations and hipocaloric diet if needed (overweight, obesity).

    Dietary Supplement: Ovapro (Lifepro)

  • No intervention
    No intervention in healthy subjects

    Healthy subjects will not recieve supplement/placebo nor dietary intervention.

Interventions

  • Dietary supplementOvapro (Lifepro)

    Dietary supplement that contains inositol, vitamin D, zinc, and curcumin.

06

What researchers measure

Primary outcomes

  1. Verify that nutritional intervention and inositol supplementation improve the symptoms of PCOS.

    To assess if there is an improvement in PCOS symptoms, both PCOSQ and Ferriman-Gallwey test and regularity of menstrual cycle will be evaluated. PCOSQ result must be assessed as 7-point scales in which 7 represents optimal function and 1 represents the poorest function. Ferriman-Gallway test gives a total score, which can range from 0 to 36. A score of ≥8 si considered a sign of androgen excess in caucausian women; a score of 8-15 indicates mild hirsutism, and \>15 indicates moderate or severe hirsutism. The classification of patients between PCOS or healthy will be carried out using Rotterdam criteria.

    Time frame: 5 years

  2. Evaluate the differences in the diversity of the intestinal microbiota depending on whether patients present PCOS or not.

    To asses the differences in alpha-diversity of the intestinal microbiota in both groups, it will be evaluated whether there are significant differences between the Shannon indices of the two groups.

    Time frame: 5 years

Secondary outcomes

  1. Evaluate significant changes in body fat mass percentage after the dietetic intervention and dietetic supplement.

    Percentage of body fat mass will be measured by bioelectrical impedance. It is considered to be high when ≥30% in women. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  2. Assess significant changes in high-sensitivity C-reactive protein (hs-CRP) as an inflammatory parameter after the dietary intervention and dietetic supplement.

    Participants will be considered to have achieved an improvement in high-sensitivity C-reactive protein levels if they normalize its value (normality values defined between 0 and 1.69mg/dl).

    Time frame: 3 years

  3. Evaluate significant changes in C3 protein as an inflammatory parameter after the dietetic intervention and dietetic supplement.

    Participants will be considered to have achieved an improvement in C3 protein if they normalize its value (normality values defined between 81 and 157mg/dl).

    Time frame: 3 years

  4. Evaluate significant changes in interleukin 1-beta (IL-1B) levels as a pro-inflammatory molecule after the dietetic intervention and dietetic supplement.

    IL-1B levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  5. Evaluate significant changes in interleukin 6 (IL-6) levels as a pro-inflammatory molecule after the dietetic intervention and dietetic supplement.

    IL-6 levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  6. Evaluate significant changes in tumor necrosis factor alpha (TNF-alpha) levels as a pro-inflammatory molecule after the dietetic intervention and dietetic supplement.

    TNF-alpha levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  7. Assess significant changes in superoxide dismutase (SOD) levels after the dietetic intervention and dietetic supplement.

    Superoxide dismutase levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  8. Evaluate if there is a significant reduction after the dietetic intervention in total ROS levels.

    Total ROS levels will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  9. Assess if there is a significant reduction after the dietetic intervention in glutathione levels.

    Total glutathione levels will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  10. Analyze if there is a significant change after the dietetic intervention in total free radicals and superoxide levels.

    Total free radicals and superoxide content will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  11. Analyze if there is a significant reduction after the dietetic intervention in mitochondrial ROS production.

    Mitochondrial ROS production will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  12. Evaluate if there is a significant improvement after the dietetic intervention in mitochondrial membrane potential.

    Mitochondrial membrane potential will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • FISABIO
    Valencia, Valencia 46020, Spain
    Recruiting
    • Celia Bañuls, PhD · Contactc.banuls@fisabio.es · 963188882
    • María Jesús Sanz Llorens, Msc · Sub investigator
    • Susana Rovira Llopis, PhD · Principal investigator
    • Celia Bañuls Morant, PhD · Principal investigator
08

References and documents

Publications

  • Sander VA, Hapon MB, Sicaro L, Lombardi EP, Jahn GA, Motta AB. Alterations of folliculogenesis in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2011 Mar;124(1-2):58-64. doi: 10.1016/j.jsbmb.2011.01.008. Epub 2011 Jan 22. PubMed 21262361 ↗
  • Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Obese and Non-obese Polycystic Ovarian Syndrome: Comparison of Clinical, Metabolic, Hormonal Parameters, and their Differential Response to Clomiphene. Indian J Endocrinol Metab. 2019 Mar-Apr;23(2):257-262. doi: 10.4103/ijem.IJEM_637_18. PubMed 31161114 ↗
  • Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, Macut D. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod. 2012 Feb;27(2):541-9. doi: 10.1093/humrep/der418. Epub 2011 Dec 5. PubMed 22144419 ↗
  • Navarro G, Allard C, Xu W, Mauvais-Jarvis F. The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring). 2015 Apr;23(4):713-9. doi: 10.1002/oby.21033. Epub 2015 Mar 6. PubMed 25755205 ↗
  • Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health. 2015 Jan 16;12:7. doi: 10.1186/1742-4755-12-7. PubMed 25595199 ↗
  • Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord. 2018 Nov 13;17(2):277-285. doi: 10.1007/s40200-018-0371-5. eCollection 2018 Dec. PubMed 30918863 ↗
  • Szczuko M, Skowronek M, Zapalowska-Chwyc M, Starczewski A. Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS). Rocz Panstw Zakl Hig. 2016;67(4):419-426. PubMed 27925712 ↗
  • Yang Y, Deng H, Li T, Xia M, Liu C, Bu XQ, Li H, Fu LJ, Zhong ZH. The mental health of Chinese women with polycystic ovary syndrome is related to sleep disorders, not disease status. J Affect Disord. 2021 Mar 1;282:51-57. doi: 10.1016/j.jad.2020.12.084. Epub 2020 Dec 27. PubMed 33388474 ↗
  • Mojaverrostami S, Asghari N, Khamisabadi M, Heidari Khoei H. The role of melatonin in polycystic ovary syndrome: A review. Int J Reprod Biomed. 2019 Dec 30;17(12):865-882. doi: 10.18502/ijrm.v17i12.5789. eCollection 2019 Dec. PubMed 31970309 ↗
  • Jiao N, Baker SS, Nugent CA, Tsompana M, Cai L, Wang Y, Buck MJ, Genco RJ, Baker RD, Zhu R, Zhu L. Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis. Physiol Genomics. 2018 Apr 1;50(4):244-254. doi: 10.1152/physiolgenomics.00114.2017. Epub 2018 Jan 26. PubMed 29373083 ↗
  • Zhang Z, Bai L, Guan M, Zhou X, Liang X, Lv Y, Yi H, Zhou H, Liu T, Gong P, Sun J, Zhang L. Potential probiotics Lactobacillus casei K11 combined with plant extracts reduce markers of type 2 diabetes mellitus in mice. J Appl Microbiol. 2021 Oct;131(4):1970-1982. doi: 10.1111/jam.15061. Epub 2021 Apr 8. PubMed 33694236 ↗
  • Bamberger C, Rossmeier A, Lechner K, Wu L, Waldmann E, Fischer S, Stark RG, Altenhofer J, Henze K, Parhofer KG. A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial. Nutrients. 2018 Feb 22;10(2):244. doi: 10.3390/nu10020244. PubMed 29470389 ↗
  • den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325-40. doi: 10.1194/jlr.R036012. Epub 2013 Jul 2. PubMed 23821742 ↗
  • Heimann E, Nyman M, Palbrink AK, Lindkvist-Petersson K, Degerman E. Branched short-chain fatty acids modulate glucose and lipid metabolism in primary adipocytes. Adipocyte. 2016 Oct 28;5(4):359-368. doi: 10.1080/21623945.2016.1252011. eCollection 2016 Oct-Dec. PubMed 27994949 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 34 months is above that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2024
First posted
Aug 13, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2029
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06551285
Lead sponsor
Celia Bañuls
Responsible party
Celia Bañuls (Principal Investigator, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana) — Sponsor-investigator
First posted
Aug 13, 2024
Start date
Feb 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Mar 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion